undamentalytics Newsletter
Sign in

Stereotaxis, Inc. (STXS) stock

Add to watchlist

Add holding +

NYSE: STXS NYSE Health Care Equipment Next results ~November 10, 2026

E Fundamentals grade

Stereotaxis, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.3

Price-to-sales vs peers

Base case. Range ~$0.3–$1.5. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Stereotaxis, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling2 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds57 adding, 38 cuttingOf 14 active managers that changed their stake, 7 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Stereotaxis files

Where Stereotaxis stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $30m, down 5.5% on a year earlier, against growth of 13.4% a quarter earlier. That puts it 90 of 103 for growth among the health care equipment companies we cover. Free-cash-flow margin fell to -51.6% from -38.3% a year earlier. The diluted share count is up 11.1% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $0.29 a share, against a share price of $0.97.

Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Stereotaxis, Inc.'s trailing-twelve-month revenue fell 5.5% year on year, with a free-cash-flow margin of -51.6%. Where it lags: change in growth rate of -18.9pp ranks 117 of 129 health care equipment companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -5.5% (-18.9pp vs the prior quarter), the 2nd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 5.5% over the last 12 months.
  • Growth slowing. The growth rate is 18.9 points lower than a quarter earlier.
  • Loss-making. Operating margin is -75.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -51.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 28.8% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q2

Filed August 12, 2026
Earnings per share
-$0.05 against an average estimate of -$0.05: missed by 7.1%
Revenue
$8m, down 12.8% on a year earlier
Share reaction
-2.8% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 10, 2026; average EPS estimate -$0.06

Stereotaxis' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.3%
  • 1 week-11.1%
  • 1 month-25.4%
  • This year-61.7%
  • 1 year-69.8%
  • 5 years-86.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$30.1M
Operating margin
-75.7%
Net margin
-74.2%
EPS (TTM, diluted)
$-0.23

Growth

Revenue growth
−5.5%
Change in growth rate
−18.9 pts
Share count change
+11.1%

Cash

Free cash flow (TTM)
-$15.5M
FCF margin
-51.6%
Stock pay % of revenue
28.8%

Earnings

Last results
August 11, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement
  3. Share issue

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Stereotaxis, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Stereotaxis, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.05 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.3 ~$0.3–$1.5 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.3 ~$0.3–$1.5 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Stereotaxis, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$0.74$0.65$0.80$1.08$5.29$5.09$6.20$2.07$1.75$2.28$2.30$0.88
Market value$16m$14m$18m$56m$334m$370m$468m$157m$141m$194m$209m$85m
+ Net debt (− = net cash)$13m$13m−$4m−$11m−$30m−$42m−$39m−$9m−$20m−$12m−$13m−$10m
Enterprise value$28m$27m$14m$45m$303m$328m$430m$149m$121m$182m$196m$75m
Multiples
Price / sales 0.4x0.4x0.6x1.9x11.5x13.9x13.4x5.6x5.3x7.2x6.5x2.8x
Price / earnings ———n/m————————
Price / free cash flow ————————————
EV / EBITDA ————————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

22 /100

Weak moat

How hard Stereotaxis's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -9.1% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 66.7%, moving by 9.6 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -39.8%; its worst year was -91.4%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -19.0% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 28.9% over five years; stock-based pay has been a median 22.9% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, after the close. Analysts expect revenue of $10m and EPS of −$0.06 (range −$0.06 to −$0.05) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.21 +16% $34m +6%
Next −$0.15 +26% $46m +33%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +10.5% on 90 days ago. In the last 30 days, 1 analyst raised Stereotaxis, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Stereotaxis, Inc., last 90 days
−$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.19 Current fiscal year, 60 days ago: −$0.19 Current fiscal year, 30 days ago: −$0.19 Current fiscal year, 7 days ago: −$0.19 Current fiscal year, Now: −$0.21 −$0.21 Next fiscal year, 90 days ago: −$0.13 Next fiscal year, 60 days ago: −$0.13 Next fiscal year, 30 days ago: −$0.13 Next fiscal year, 7 days ago: −$0.13 Next fiscal year, Now: −$0.15 −$0.15

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.19−$0.13
60 days ago −$0.19−$0.13
30 days ago −$0.19−$0.13
7 days ago −$0.19−$0.13
Now −$0.21−$0.15

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.05 −$0.05 −7.1%
Dec 2025 −$0.07 −$0.06 +7.7%
Sept 2025 −$0.06 −$0.07 −16.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026123
  2. Sep 2026224

Counts of recommendations published by analysts covering Stereotaxis, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.1%
of tradable shares
Days to cover
11.26
at average volume
Short interest, 1 month
+7%
to October 15, 2026
Held by institutions
49%
of shares
Held by insiders
15.2%
of shares
Employees
131
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −69.8%

$2.91 on October 31, 2025 to $0.88

ThenNowEffect
Revenue (last 12 months) $32m $30m −5.5%
P/S multiple 8.0x 2.8x −64.5%
Share count 87m 97m −10.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −47.3%

$1.67 on November 3, 2023 to $0.88

ThenNowEffect
Revenue (last 12 months) $29m $30m +2.4%
P/S multiple 4.4x 2.8x −35.7%
Share count 77m 97m −19.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
STXS+22%−67%−16%+30%+1%−62%
Industry peers (median)−9%−37%−8%−20%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
STXS50%25%58%42%50%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
STXS−50%−77%−48%−46%−41%−69%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 92% from June 21, 2021 to October 30, 2026. Getting back needed a 1083% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.86 – $2.85
From 52-week high
−69.1%
vs 50-day average
−27.2%
vs 200-day average
−48.2%
Volatility (1 year)
52%
Beta vs S&P 500
1.66

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±8.1%
After a week
3 up, 9 down
typical move ±9.6%
After a month
6 up, 6 down
typical move ±12.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 −2.8% −0.1% −5.6% −9.7%
May 12, 2026 −1.6% +0.4% −8.0% −3.2%
March 9, 2026 −3.9% +0.7% −6.8% −5.9%
November 12, 2025 −21.4% −1.6% −21.4% −16.8%
August 7, 2025 +11.1% +0.7% +28.9% +28.0%
July 17, 2025 −2.9% +0.5% −6.3% +14.2%
May 12, 2025 −0.9% +4.0% −1.9% +4.2%
March 3, 2025 −12.6% −2.9% −14.1% −17.0%
November 12, 2024 +18.9% −0.3% +10.8% +18.4%
August 12, 2024 +7.5% +1.7% +2.1% +16.6%
May 13, 2024 −4.1% +0.5% −4.1% −11.0%
March 4, 2024 −10.0% −1.1% −5.2% +9.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Stereotaxis, Inc. in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Stereotaxis, Inc.
$20M $25M $30M $35M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $29.5M Revenue (TTM), FY23 Q4: $26.8M Revenue (TTM), FY24 Q1: $27.1M Revenue (TTM), FY24 Q2: $23.7M Revenue (TTM), FY24 Q3: $25.1M Revenue (TTM), FY24 Q4: $26.9M Revenue (TTM), FY25 Q1: $27.5M Revenue (TTM), FY25 Q2: $31.8M Revenue (TTM), FY25 Q3: $30.1M Revenue (TTM), FY25 Q4: $32.4M Revenue (TTM), FY26 Q1: $31.2M Revenue (TTM), FY26 Q2: $30.1M $30.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $29.5M
FY23 Q4 $26.8M
FY24 Q1 $27.1M
FY24 Q2 $23.7M
FY24 Q3 $25.1M
FY24 Q4 $26.9M
FY25 Q1 $27.5M
FY25 Q2 $31.8M
FY25 Q3 $30.1M
FY25 Q4 $32.4M
FY26 Q1 $31.2M
FY26 Q2 $30.1M
Revenue growth, TTM YoY Stereotaxis, Inc.
-20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 1.4% Revenue growth, TTM YoY, FY23 Q4: -4.9% Revenue growth, TTM YoY, FY24 Q1: -2.0% Revenue growth, TTM YoY, FY24 Q2: -19.1% Revenue growth, TTM YoY, FY24 Q3: -14.8% Revenue growth, TTM YoY, FY24 Q4: 0.5% Revenue growth, TTM YoY, FY25 Q1: 1.5% Revenue growth, TTM YoY, FY25 Q2: 33.9% Revenue growth, TTM YoY, FY25 Q3: 19.6% Revenue growth, TTM YoY, FY25 Q4: 20.3% Revenue growth, TTM YoY, FY26 Q1: 13.4% Revenue growth, TTM YoY, FY26 Q2: -5.5% -5.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 1.4%
FY23 Q4 -4.9%
FY24 Q1 -2.0%
FY24 Q2 -19.1%
FY24 Q3 -14.8%
FY24 Q4 0.5%
FY25 Q1 1.5%
FY25 Q2 33.9%
FY25 Q3 19.6%
FY25 Q4 20.3%
FY26 Q1 13.4%
FY26 Q2 -5.5%
Operating margin (TTM) Stereotaxis, Inc.
-100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -71.1% Operating margin (TTM), FY23 Q4: -81.6% Operating margin (TTM), FY24 Q1: -77.4% Operating margin (TTM), FY24 Q2: -91.4% Operating margin (TTM), FY24 Q3: -89.2% Operating margin (TTM), FY24 Q4: -91.9% Operating margin (TTM), FY25 Q1: -94.2% Operating margin (TTM), FY25 Q2: -75.1% Operating margin (TTM), FY25 Q3: -80.1% Operating margin (TTM), FY25 Q4: -68.3% Operating margin (TTM), FY26 Q1: -71.0% Operating margin (TTM), FY26 Q2: -75.7% -75.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -71.1%
FY23 Q4 -81.6%
FY24 Q1 -77.4%
FY24 Q2 -91.4%
FY24 Q3 -89.2%
FY24 Q4 -91.9%
FY25 Q1 -94.2%
FY25 Q2 -75.1%
FY25 Q3 -80.1%
FY25 Q4 -68.3%
FY26 Q1 -71.0%
FY26 Q2 -75.7%
FCF margin (TTM) Stereotaxis, Inc.
-60% -40% -20% 0% FY21 Q2 FY22 Q1 FY22 Q4 FY26 Q2 FCF margin (TTM), FY21 Q2: -1.8% FCF margin (TTM), FY21 Q3: -4.8% FCF margin (TTM), FY21 Q4: -12.4% FCF margin (TTM), FY22 Q1: -22.0% FCF margin (TTM), FY22 Q2: -29.7% FCF margin (TTM), FY22 Q3: -35.4% FCF margin (TTM), FY22 Q4: -38.3% FCF margin (TTM), FY23 Q1: -38.3% FCF margin (TTM), FY23 Q2: -40.0% FCF margin (TTM), FY23 Q3: -33.8% FCF margin (TTM), FY23 Q4: -35.5% FCF margin (TTM), FY26 Q2: -51.6% -51.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY21 Q2 -1.8%
FY21 Q3 -4.8%
FY21 Q4 -12.4%
FY22 Q1 -22.0%
FY22 Q2 -29.7%
FY22 Q3 -35.4%
FY22 Q4 -38.3%
FY23 Q1 -38.3%
FY23 Q2 -40.0%
FY23 Q3 -33.8%
FY23 Q4 -35.5%
FY26 Q2 -51.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 51 54 42 47 38 35 38 32 31 29 29 27 35 28 27 27 32 30
Gross profit 34 38 29 32 27 27 27 25 20 24 23 19 23 18 15 15 17 17
EBITDA −22 −17 −30 −9 −8 −5 −5 −6 −5 −2 −5 −7 −13 −18 −21 −24 −21 −22
Operating income −24 −19 −32 −11 −9 −5 −5 −6 −6 −2 −5 −7 −13 −19 −22 −25 −22 −23
Net income −27 −20 −32 −9 −69 −5 −7 −5 −6 0 −5 −7 −11 −18 −21 −24 −22 −22
Diluted EPS −$0.63 −$3.59 −$5.84 −$1.33 −$5.95 −$0.26 −$0.35 −$0.54 −$0.32 −$0.03 −$0.10 −$0.11 −$0.16 −$0.26 −$0.27 −$0.30 −$0.25 −$0.23
Growth (year on year)
Revenue — +5.7% −22.3% +10.9% −18.3% −7.9% +7.6% −14.6% −3.2% −5.8% −1.5% −7.9% +31.5% −19.6% −4.9% +0.5% +20.3% −5.5%
Margins
Gross margin 66.7% 71.2% 70.2% 68.3% 71.1% 76.5% 72.3% 76.6% 65.5% 80.5% 78.8% 71.2% 66.3% 65.6% 55.5% 54.2% 52.7% 55.6%
EBITDA margin −42.6% −31.9% −72.6% −20.0% −20.8% −14.2% −13.5% −18.8% −17.2% −6.6% −16.3% −24.7% −36.5% −65.2% −79.4% −89.7% −66.4% −73.5%
Operating margin −46.6% −35.1% −76.1% −22.8% −23.2% −15.4% −14.4% −20.0% −19.0% −8.4% −16.7% −25.2% −36.8% −66.7% −81.6% −91.9% −68.3% −75.7%
Net margin −53.8% −36.9% −76.3% −19.8% −180.8% −14.9% −19.5% −16.4% −18.9% 0.4% −15.9% −25.0% −30.6% −65.0% −77.4% −89.3% −66.8% −74.2%
Free-cash-flow margin — — — — — — — −21.7% −15.3% −9.6% −16.1% −13.5% −12.4% −38.3% −35.5% −31.7% −42.6% −51.6%
Cash flow
Cash from operations −22 −19 −32 −12 −6 −9 −3 −7 −5 −3 −5 −4 −3 −8 −9 −8 −14 −15
Capital spending — — — — — — — 0 0 0 0 0 1 2 0 0 0 0
Free cash flow — — — — — — — −7 −5 −3 −5 −4 −4 −11 −10 −9 −14 −16
Stock-based pay 4 2 2 2 1 2 1 1 1 1 1 3 9 11 11 10 10 9
Free cash flow after stock pay — — — — — — — −8 −6 −3 −6 −7 −14 −21 −20 −19 −24 −24
Balance sheet
Cash 31 35 14 8 14 7 6 9 4 11 30 44 39 9 20 12 13 10
Total debt 0 29 38 29 19 18 18 21 0 0 0 2 — 0 0 0 0 0
Net debt (negative = net cash) −31 −6 25 21 5 11 13 13 −4 −11 −30 −42 −39 −9 −20 −12 −13 −10
Diluted shares — 6m 5m 7m 12m 20m 21m 22m 23m 52m 63m 73m 76m 76m 81m 85m 91m 97m
Returned to shareholders
Dividends — — — — 0 0 0 0 0 — — 0 0 0 0 0 0 0
Total returned — — — — 0 0 0 0 0 — — 0 0 0 0 0 0 0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $56m
Short-term assets $38mLonger-term assets $18m
What it owes, and who funded it · $50m
Short-term liabilities $27mLonger-term liabilities $11mShareholders' equity $12m
  • Short-term assets cover short-term liabilities $38m of assets due within a year against $27m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $38m short-term assets against $11m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Stereotaxis, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$0
Returned to shareholders
0%
of free cash flow
Diluted share count
+11.1%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value
R&D spending
33.4%
of revenue
Days sales outstanding
92 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated STXS POCI OBIO RVP QTI UTMD Median
Revenue, last 12 months $30m $32m $32m $34m $26m $36m $99m
Revenue growth, last 12 months −5.5% 65.2% 986.1% −11.2% 220.0% −7.0% 9.2%
Revenue growth, 3-year average 0.8% 14.4% 94.5% −14.7% — −11.4% 13.5%
Revenue growth, latest quarter −12.8% 42.0% −89.5% −31.1% 103.2% −14.3% 10.2%
Gross margin 55.6% 17.2% 99.5% −1.4% 40.4% 57.9% 61.2%
Operating margin −75.7% −11.1% −181.4% −66.9% −24.8% 28.4% −8.5%
Operating margin, 3-year average −80.7% −18.2% <−999% −52.5% −140.1% 31.2% −17.9%
Net margin −74.2% −11.5% −184.6% −9.9% −77.3% 29.0% −12.0%
Cash from operations / revenue −50.9% −4.9% −182.4% −14.6% −47.2% 32.8% −1.9%
Free-cash-flow margin −51.6% −5.8% −184.8% −37.7% −48.2% 31.7% −3.9%
Free-cash-flow margin, 3-year average −37.3% −13.4% <−999% −20.6% — 35.4% −7.0%
Stock pay / revenue 28.8% 3.5% 34.8% 10.7% 5.8% 1.1% 6.1%
Change in share count 11.1% 25.6% 58.1% 0.0% 256.7% −4.8% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth -5.5% 9.1% 109 of 129
Change in growth rate Growth -18.9pp -0.6pp 117 of 129
Gross margin Profitability 55.6% 61.9% 78 of 123
Operating margin Profitability -75.7% -8.3% 97 of 132
Net margin Profitability -74.2% -12.0% 97 of 133
Free-cash-flow margin Cash generation -51.6% -3.4% 94 of 128
Stock pay as % of revenue Cash generation 28.8% 6.1% 105 of 123
Change in share count Balance sheet 11.1% 3.3% 87 of 115
Days sales outstanding Balance sheet 92 days 57 days 105 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Disposables Service and Accessories $22.2M 68.4% ▲ 21.2%
Systems $10.2M 31.6% ▲ 18.4%
Geography
Region Revenue Share YoY
Outside the US $19.5M 60.3% ▲ 44.6%
United States $12.9M 39.7% ▼ 4.2%

From Stereotaxis, Inc.'s 10-K filed March 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$73.2M
Institutions reporting
107
Shares held vs prior quarter
▲ 0.3%
Positions opened / closed
13 / 16

Top buyers and sellers, Q2 2026: 57 institutions bought and 38 sold ; the biggest buyer was Blackrock, Inc (+441K shares) and the biggest seller Renaissance Technologies LLC (−357K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Dafna Capital Management LLC $23.5M 13.7M 32.1% 0.0%
Blackrock, Inc. $7.6M 4.4M 10.3% ▲ 11.1%
Lagoda Investment Management, L.P. $7.1M 4.1M 9.7% ▼ 5.2%
Vanguard Capital Management LLC $5.2M 3.0M 7.2% ▲ 1.6%
Arbiter Partners Capital Management LLC $5M 2.9M 6.8% 0.0%
Geode Capital Management, LLC $3.3M 1.9M 4.5% ▲ 13.1%
Essex Investment Management Co LLC $2.6M 1.5M 3.6% ▼ 4.3%
Archon Capital Management LLC $2.1M 1.2M 2.9% 0.0%
Warberg Asset Management LLC $1.9M 1.1M 2.6% ▲ 1.3%
State Street Corp $1.6M 917K 2.2% ▼ 4.3%
Alphacentric Advisors LLC $1M 600K 1.4% 0.0%
Vanguard Fiduciary Trust Co $1M 589K 1.4% ▲ 11.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Stereotaxis, Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $66,600 2 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $66,600 net buying
Insider Date Trade Shares Price Value
Isaac Paul J Director November 17, 2025 Buy 10,000 $2.18 $21,800
Isaac Paul J Director November 14, 2025 Buy 20,000 $2.24 $44,800

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 12, 2026
  • March 9, 2026
  • November 12, 2025
  • August 7, 2025
  • July 17, 2025

Recent SEC filings

Data status

When each part of this page on Stereotaxis, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Stereotaxis, Inc. in brief

What does Stereotaxis, Inc. do?
Stereotaxis, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Stereotaxis, Inc.'s stock ticker?
Stereotaxis, Inc. trades under the ticker STXS on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Stereotaxis, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Stereotaxis, Inc. reported revenue of $30.1M, 5.5% lower than a year earlier, according to its SEC filings.
What is Stereotaxis, Inc.'s free cash flow?
Stereotaxis, Inc.'s free-cash-flow margin is -51.6% of revenue over the trailing twelve months, ranking 94 of the 128 health care equipment companies we cover.
Who are Stereotaxis, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Dafna Capital Management LLC, Blackrock, Inc. and Lagoda Investment Management, L.P. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Stereotaxis, Inc.'s market cap?
On November 2, 2026, Stereotaxis, Inc.'s market capitalisation was about $85.1M and net debt of -$10.5M. Market figures come from third-party market data and may be delayed.
Does Stereotaxis, Inc. pay a dividend?
Stereotaxis, Inc. reported no dividend payments in its trailing twelve months of filings.
Who are Stereotaxis, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Stereotaxis, Inc. are Precision Optics Corporation, Inc., Orchestra Biomed Holdings, Inc., Retractable Technologies Inc, QT Imaging Holdings, Inc. and Utah Medical Products Inc. The side-by-side comparison below sets their revenue, margins and growth against Stereotaxis, Inc.'s.
Are insiders buying or selling Stereotaxis, Inc. stock?
Over the last 12 months, Stereotaxis, Inc.'s directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Stereotaxis, Inc.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Stereotaxis, Inc. announces its own schedule.